# Ash A. Alizadeh

Source: https://onco.cc/people/ash-alizadeh/  
OnCo record `ash-alizadeh` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Co-invented the CAPP-Seq method for reading tumour DNA in blood and used it to track lymphoma and lung cancer.

## Summary

Ash Alizadeh is Professor of Medicine (Oncology) at Stanford University, within the Stanford Cancer Institute. An oncologist and computational biologist, he co-developed CAPP-Seq and phased variant enrichment for ultrasensitive circulating tumour DNA detection, applied to minimal residual disease in lymphoma and lung cancer, and led early work on tumour cell-of-origin classification in diffuse large B-cell lymphoma. His papers include a Nature Medicine report of an ultrasensitive method for quantitating circulating tumour DNA with broad patient coverage and the Nature paper identifying distinct types of diffuse large B-cell lymphoma by gene expression profiling. He continues to work on liquid biopsy and molecular residual disease testing.

## Fields

- Kind: Person
- Last checked: 2026-09-08
- Role: Professor of Medicine (Oncology), Stanford University
- Specialisms: Circulating tumour DNA; Lymphoma; Computational oncology

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Ash_Alizadeh
- Stanford profile: https://profiles.stanford.edu/search?q=Ash%20A.%20Alizadeh
- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Alizadeh%20AA%5BAuthor%5D
- Google Scholar: https://scholar.google.com/scholar?q=Ash%20A.%20Alizadeh

## Connected records

- cancers: [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- technologies: [Liquid biopsy (ctDNA)](https://onco.cc/technologies/liquid-biopsy/), [MRD / molecular residual disease testing](https://onco.cc/technologies/mrd-testing/)
- institutions: [Stanford Health Care / Stanford Cancer Institute](https://onco.cc/institutions/stanford/)
- terms: [Circulating tumour DNA (ctDNA)](https://onco.cc/terms/ctdna/), [Minimal / molecular residual disease (MRD)](https://onco.cc/terms/mrd/)
- key papers: [Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumour DNA](https://onco.cc/key-papers/paper-scherer-ctdna-lymphoma-subtypes-genome-evolution-sci-transl-med-2016/)
- roadmaps: [Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting](https://onco.cc/roadmaps/lymphoma-roadmap/)

---
JSON: https://onco.cc/api/v1/entities/ash-alizadeh.json